Nwam LLC Astrazeneca PLC Transaction History

Nwam LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$61.03 - $69.57 $55,232 - $62,960	-905 Reduced 11.32%	7,089 $480,000
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $6,003 - $6,720	-97 Reduced 1.2%	7,994 $538,000
Q3 2023 Oct 31, 2023	BUY	$64.85 - $71.7 $17,185 - $19,000	265 Added 3.39%	8,091 $547,000
Q2 2023 Aug 09, 2023	SELL	$69.91 - $75.81 $1,957 - $2,122	-28 Reduced 0.36%	7,826 $560,000
Q1 2023 May 12, 2023	SELL	$63.15 - $71.6 $12,630 - $14,319	-200 Reduced 2.48%	7,854 $545,000
Q4 2022 Feb 07, 2023	BUY	$54.21 - $70.44 $30,791 - $40,009	568 Added 7.59%	8,054 $546,000
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $15,852 - $40,589	299 Added 4.16%	7,486 $411,000
Q2 2022 Aug 10, 2022	SELL	$59.26 - $71.14 $162,490 - $195,065	-2,742 Reduced 27.62%	7,187 $471,000
Q1 2022 May 12, 2022	BUY	$55.72 - $67.12 $184,433 - $222,167	3,310 Added 50.01%	9,929 $659,000
Q4 2021 Feb 10, 2022	BUY	$54.02 - $63.83 $166,975 - $197,298	3,091 Added 87.61%	6,619 $386,000
Q3 2021 Nov 03, 2021	BUY	$55.56 - $60.79 $196,015 - $214,467	3,528 New	3,528 $212,000

1,334

490M

4.99M

3.19M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $240B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

Stay updated on Nwam LLC with notifications on news.